AstraZeneca

News & Analysis as of

European Union: Assessment Of IP Licensing Agreements Under EU Competition Law*

In recent years there has been a remarkable expansion of antitrust enforcement in the area of intellectual property (IP). This trend is illustrated by an increasing willingness of the European Commission (the Commission) and...more

AstraZeneca AB v. Hanmi USA, Inc. (Fed. Cir. 2013)

A classic example of product "evergreening" is how AstraZeneca used its experience with its omeprazole franchise (sold for over a decade as Prilosec®) to promote an alternative form of the drug, Nexium® (particularly, the...more

Non-infringement holding showcases the importance of a patent’s written description

In a unanimous panel decision, the Federal Circuit found that Hanmi Pharmaceutical Co. Ltd.’s esomeprazole (Nexium®) does not infringe two AstraZeneca patents listed in the Orange Book for its Nexium® product. AtraZeneca v....more

Conflicting Results from Ontario Appellate Courts in Motions to Strike Claims in Proposed Class Actions

Ontario’s appellate courts have released two decisions in the past week addressing the issue of when claims ought to be struck in the context of proposed class proceedings for failing to disclose a cause of action. First, a...more

In re Rosuvastatin Calcium Patent Litigation (Fed. Cir. 2012)

Late last year, in AstraZeneca v. Aurobindo (In re Rosuvastatin Calcium Patent Litigation), the Federal Circuit affirmed that a reissue patent covering the active ingredient of Crestor® was valid, enforceable, and infringed...more

Antitrust and Life Sciences Alert: EU Court of Justice Hears Appeal of Abuse of Dominance Finding Against AstraZeneca

On 12 January 2012, the Court of Justice of the European Union heard AstraZeneca's appeal of the General Court's judgment largely upholding the European Commission's decision fining AstraZeneca €60 million for abuse of...more

6 Results
|
View per page
Page: of 1